{"filings":[{"id":68281,"accession_number":"0001437749-26-016726","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2026-05-13T20:12:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.","Net loss $3.5M ($0.90/share) vs $3.8M ($4.38/share) a year ago.","Cash $9.3M at March 31, down from $12.0M at Dec 31, 2025.","NEUTRALIZE-AKI trial enrolled 198 of 339 patients; PMA submission efforts initiated.","Added 7 children’s hospitals, now 17 total, targeting 15 more in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":495000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95981,"accession_number":"0001437749-26-013653","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SeaStar Medical's securities class action lawsuit dismissed with prejudice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class action filed July 5, 2024, alleged material misstatements culminating in March 2024 restatement.","Parties filed Stipulation of Dismissal with Prejudice on April 21, 2026.","Court ordered dismissal with prejudice on April 27, 2026, ending litigation.","Dismissal removes potential compensatory damages and other remedies sought."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109459,"accession_number":"0001437749-26-009780","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).","Net loss Q4 2025 $2.9M ($0.80/share) vs $4.4M ($8.98/share) Q4 2024; cash $12.0M (up from $1.8M).","QUELIMMUNE expanded to 16 children's hospitals; SAVE Registry enrollment completed (50 patients).","NEUTRALIZE-AKI trial >50% enrolled (181/339); modular PMA submission for adult AKI initiated.","Guides 2026 net product revenue ~$2M; plans to add 15 more hospital sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109458,"accession_number":"0001437749-26-001541","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SeaStar Medical regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on Jan 20, 2026 confirming compliance with Minimum Bid Price Rule 5550(a)(2).","Common stock (ICU) and warrants (ICUCW) remain listed on Nasdaq.","Previous deficiency resolved; no delisting risk from bid price requirement.","Company continues operations without further bid price condition at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125961,"accession_number":"0001437749-25-038701","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K/A","filed_at":"2025-12-23T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"SeaStar Medical moves reverse stock split effective date to Jan 5, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-10 reverse stock split effective 12:01 AM ET on January 5, 2026.","Common stock will trade on Nasdaq post-split under symbol ICU starting Jan 5.","Post-split shares outstanding approximately 3.8 million.","Objective: regain compliance with Nasdaq $1 minimum bid price requirement.","Stockholders' shares automatically adjusted; no fractional shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125964,"accession_number":"0001437749-25-038276","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["3.03","5.07"],"status":"ready","headline":"SeaStar Medical shareholders approve 1-for-10 reverse stock split effective Jan 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved with 16.5M for, 5.6M against; authorized shares cut by 25M to 425M.","Split effective 12:01 AM ET Jan 2, 2026; post-split shares outstanding ~3.8M.","No fractional shares; round-up to next whole number. Warrants/options proportionally adjusted.","Symbol 'ICU' unchanged; trading on Nasdaq begins split-adjusted Jan 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125963,"accession_number":"0001437749-25-035449","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SeaStar Medical appoints Michael Messinger as CFO effective Nov 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Messinger appointed CFO; receives $15,000 monthly fee under consulting agreement.","Agreement terminable with 30 days' notice; effective Nov 14, 2025.","25+ years experience; former CFO of ContraFect, led Nasdaq IPO and $90M BARDA contract.","BBA in accounting from University of Michigan; started career at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125962,"accession_number":"0001437749-25-034834","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q3 revenue $0.2M, net loss $3.5M; QUELIMMUNE orders rising","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $0.2M (Q3 2024: $0.1M); net loss $3.5M ($0.13/sh) vs $4.5M ($1.10/sh) a year ago.","Cash $13.8M at Sep 30, 2025, up from $1.8M at Dec 31, 2024; raised $12.4M in Q3 via equity and warrant exercise.","Three top children's hospitals adopted QUELIMMUNE; Q4 orders to date exceed full Q3 orders.","NEUTRALIZE-AKI trial interim analysis showed positive safety/efficacy signal; enrollment target raised to 339 patients (146 enrolled).","QUELIMMUNE SAVE registry shows 76% 60-day and 71% 90-day survival in 21 pediatric AKI patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":814000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142706,"accession_number":"0001437749-25-030023","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SeaStar Medical restores CEO, CMO salaries and director retainers after 20% cut; monthly expenses rise ~$50K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Eric Schlorff and CMO Kevin Chung salaries restored to original levels effective Oct 1, 2025.","Director retainer fees also restored to original levels after 20% reduction in June 2025.","Monthly operating expenses expected to increase by approximately $50,000 due to these and other actions.","Board approved the increases on September 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142705,"accession_number":"0001193125-25-215608","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SeaStar Medical DSMB recommends continue NEUTRALIZE-AKI trial; enrollment target raised to 339","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB reports zero device-related safety issues in first 100 patients; recommends continuation of pivotal AKI trial.","Enrollment target increased from 200 to 339 patients to meet statistical power; 137 patients enrolled to date.","Estimated enrollment completion near end of 2026 based on current rate and new site additions.","QUELIMMUNE pediatric registry shows 75% 28-day survival and no device-related safety events in first 20 patients.","Company highlights potential clinical benefit signal; plans to manage capital to support milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142704,"accession_number":"0001831868-25-000014","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SeaStar Medical terminates CFO David Green, appoints CEO Eric Schlorff as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Green terminated as CFO and Treasurer effective Aug 14, 2025; termination without cause.","Severance expected: ~$300k base salary over 12 months, COBRA, and accelerated RSU vesting.","CEO Eric Schlorff appointed interim CFO and Treasurer while permanent search is conducted.","Controller Bradford Towne appointed principal accounting officer effective Aug 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142695,"accession_number":"0001831868-25-000011","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K/A","filed_at":"2025-08-14T23:59:59+00:00","items":["2.01","2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.","NEUTRALIZE-AKI pivotal trial enrollment reached 125 of 200 patients (60%+); interim DSMB recommendations expected Q3 2025.","Added three new top children's hospital customers; SAVE Surveillance Registry showed 75% 28-day survival in first 20 patients.","Raised total $20.8M through offerings in June ($12.4M), July and August 2025 ($8.4M) to extend cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":631000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142703,"accession_number":"0001831868-25-000006","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.","NEUTRALIZE-AKI trial enrolled 125 of 200 patients; interim DSMB recommendations expected Q3 2025.","Three new children's hospitals adopted QUELIMMUNE; SAVE registry shows 75% 28-day survival in 20 pediatric patients.","Raised $12.4M in June and $8.4M in two July/August 2025 offerings; cash at June 30 was $6.3M.","CMS agreed to cover clinical trial expenses for NEUTRALIZE-CRS; DoD awarded $2M grant for burn research."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":631000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142702,"accession_number":"0000950170-25-105906","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SeaStar Medical resumes ATM offering for up to $2.17M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company had sold $6.8M under ATM prior to suspension on July 10, 2025.","Resumes sales under ATM agreement for aggregate offering price up to $2,166,305.","Shares offered via existing shelf registration statement (Form S-3, effective Dec 22, 2023).","No minimum offering amount; proceeds for general corporate purposes.","Counsel's opinion on validity of shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142701,"accession_number":"0000950170-25-103274","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical receives Nasdaq bid price deficiency notice; 180-day cure period until Jan 27, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified SeaStar that common stock (ICU) closing bid price below $1.00 for 30 consecutive trading days.","Company has 180 days, until Jan 27, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","No immediate effect on listing; company intends to monitor and consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142694,"accession_number":"0000950170-25-103356","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K/A","filed_at":"2025-08-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Deficiency letter received July 31, 2025; closing bid price below $1.00 for 30 consecutive business days.","180-day compliance period ends January 27, 2026 to regain listing under Rule 5550(a)(2).","Compliance can be regained if closing bid price is at least $1.00 for 10 consecutive business days.","Company intends to monitor bid price and consider available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142700,"accession_number":"0000950170-25-101408","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"SeaStar Medical raises $4.4M in registered direct offering and private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4,960,544 shares at $0.887 per share, plus unregistered warrants for same number at $0.762.","Gross proceeds ~$4.4M; net proceeds after fees ~$3.9M.","H.C. Wainwright acted as exclusive placement agent; fees include 7% cash and warrants.","Warrants exercisable immediately for 5 years; shares offered via effective S-3 shelf.","Use of proceeds: general corporate purposes, working capital, capex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142699,"accession_number":"0000950170-25-096244","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SeaStar Medical appoints Jennifer Baird as Board Chair; Rick Barnett resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer A. Baird appointed Chair of the Board and Chair of Nominating & Corporate Governance Committee.","Rick J. Barnett resigned as Chairman, Chair of Nominating & CG Committee, and Compensation Committee member effective July 14, 2025.","Barnett's resignation was for personal reasons and not due to any disagreement with SeaStar.","Baird has served as director since 2024 and brings healthcare product development and M&A experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142698,"accession_number":"0001213900-25-063450","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"SeaStar Medical raises ~$4M in registered direct offering plus warrants at $0.763/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 5,242,464 shares (or equivalents) at $0.763 per share, plus unregistered warrants for equal number at $0.638.","Gross proceeds ~$4.0M; net proceeds expected ~$3.6M after fees; expected to close July 11, 2025.","H.C. Wainwright & Co. is exclusive placement agent, receiving 7.0% cash fee and warrants exercisable at $0.9538.","Company agrees to 45-day lockup on equity issuance and 6-month ban on variable rate transactions post-closing.","Net proceeds to be used for general corporate purposes including working capital and capital expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142697,"accession_number":"0000950170-25-094442","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SeaStar Medical shareholders approve board, equity plan amendment, Lincoln Park issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Eric Schlorff (2,369,794 for) and Kenneth Van Heel (2,674,923 for) as Class III directors.","Approved amendment to 2022 Omnibus Equity Incentive Plan: shares increased from ~570K to 2,070,457; evergreen provision removed.","Approved potential future sale of common stock to Lincoln Park that could exceed 19.99% of outstanding shares (2,596,164 for).","Ratified WithumSmith+Brown as independent auditor for FY2025 (6,168,023 for).","Adjournment proposal approved (5,240,780 for) to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142696,"accession_number":"0000950170-25-093142","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SeaStar Medical regains Nasdaq equity compliance; needs funds by end of July","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Confirmed compliance with Nasdaq's $2.5M minimum stockholders' equity requirement; listing matter closed.","Nasdaq warned company must raise additional funds or will be below requirement by end of July 2025.","Subject to Mandatory Panel Monitor until July 1, 2026; future non-compliance may trigger delist determination.","CEO Schloff highlights focus on commercializing QUELIMMUNE and NEUTRALIZE-AKI trial for AKI patients.","Company previously received Panel exception through June 22, 2025; compliance now evidenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160770,"accession_number":"0000950170-25-088707","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","5.02","7.01","8.01"],"status":"ready","headline":"SeaStar Medical raises $4M in public offering, cuts executive salaries by 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SeaStar Medical priced a public offering of 6,153,847 shares, pre-funded warrants, and Series A/B warrants at $0.65 per combined unit, expecting approximately $4M gross proceeds.","The company reduced CEO Eric Schlorff, CFO David Green, and CMO Kevin Chung's annual base salaries by 20% to cut monthly operating expenses by about $50,000.","Nasdaq granted an exception until June 22, 2025, for SeaStar Medical to demonstrate compliance with the $2.5M stockholders' equity requirement; company believes it is now compliant.","In May and June 2025, approximately $1.2M of employee compensation and director fee liabilities were extinguished through waivers.","The offering closed on June 23, 2025, with H.C. Wainwright as placement agent; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160769,"accession_number":"0001213900-25-053463","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO and CMO waive 2023 and 2024 bonuses to reduce liabilities","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Eric Schlorff and CMO Dr. Kevin Chung agreed to waive earned bonuses for 2023 and 2024 fiscal years.","Bonus release agreements aim to reduce company liabilities; consideration is continued employment at current pay.","Agreements include a release of claims against the company for compensation-related matters.","Dollar amount of waived bonuses is not disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160768,"accession_number":"0000950170-25-071390","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.","Net loss of $3.8M ($0.44/share) vs $12.7M ($4.73/share) a year ago.","NEUTRALIZE-AKI trial 50% enrolled; interim analysis by DSMB expected Q3 2025.","Two new Breakthrough Device Designations for SCD therapy in cardiac surgery (adult & ped).","Cash $5.3M as of March 31, 2025 vs $1.8M Dec 31, 2024; $6M offering closed Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":293000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160767,"accession_number":"0000950170-25-058860","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"SeaStar Medical in $15M equity line with Lincoln Park Capital Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to buy up to $15M of common stock over 36-month period.","Company may direct up to 40k share purchases daily; limits rise with stock price thresholds.","Purchase price set at 97% of a formula based on lowest sale price and average of three lowest closing prices.","Company issued 236,406 commitment shares to Lincoln Park as consideration.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178966,"accession_number":"0000950170-25-046827","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SeaStar Medical stockholders approve warrant proposals at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of Common Warrants and shares: 2,116,949 for, 293,443 against.","Extension of Series B Warrants term approved: 2,117,817 for, 292,249 against.","Adjournment proposal passed: 2,119,244 for, 295,083 against.","Votes held on March 28, 2025; all proposals required for Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178965,"accession_number":"0000950170-25-046069","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.","First net revenue of $0.1M from QUELIMMUNE pediatric AKI therapy approved via HDE in Q1 2024.","NEUTRALIZE AKI pivotal trial enrolled 94 of 200 patients; added 14 sites in 2024.","Raised ~$31M in capital and reduced debt; $6M registered direct financing completed Feb 2025.","Cash and short-term investments $1.8M at Dec 31, 2024, before February financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178964,"accession_number":"0000950170-25-043183","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SeaStar Medical special meeting adjourned due to lack of quorum; reconvened March 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting held March 20, 2025 failed to achieve a quorum.","Meeting adjourned to March 28, 2025 at 10:00 AM MDT.","Company will continue soliciting stockholder votes until reconvened meeting.","All valid proxies submitted before original meeting remain valid unless revoked.","Record date remains January 31, 2025 per definitive proxy statement filed Feb 28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178963,"accession_number":"0000950170-25-038314","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel grants SeaStar Medical continued listing exception until June 22, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing subject to compliance with Nasdaq Listing Rule 5550(b)(2) (MVLS Rule) requiring $35M market value by June 22, 2025.","Company must file public disclosure describing equity-increasing transactions and provide updated fundraising plans and income projections by June 22, 2025.","SeaStar is continuing fundraising efforts begun in 2024 and states confidence in meeting all requirements within the specified timeframes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178962,"accession_number":"0001213900-25-009435","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"SeaStar Medical raises ~$6M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6M; offering priced at $1.70 per share (or pre-funded warrant) with accompanying warrant.","3,529,412 shares (or pre-funded warrants at $0.001) + warrants to purchase 3,529,412 shares at $1.70.","Pre-funded warrants exercisable immediately; common warrants exercisable after shareholder approval, expire 5 yrs later.","Concurrently adjusted Prior Warrants exercise price to $1.70 and extended Series B term to Jan 30, 2029 (subject to approval).","Net proceeds for general corporate purposes; expected closing Feb 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178961,"accession_number":"0000950170-25-011835","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical receives Nasdaq public reprimand for Rule 5635(d) violation; listing unaffected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff issued public reprimand for failure to obtain shareholder approval for issuance of 625,722 shares below minimum price in amendments to convertible notes and warrants.","Company bought back all remaining additional warrants; no outstanding balance on notes, and shareholders ratified transaction at Nov. 2024 special meeting.","Delisting was deemed not appropriate; listing of common stock remains unaffected.","118,207 shares from warrant exercise and 170,625 from additional warrants were issued at prices below the floor price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178960,"accession_number":"0001213900-25-002847","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SeaStar Medical reports 5,997,246 shares outstanding; updates on clinical and commercial progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2024, common shares outstanding: 5,997,246 (Jan 8, 2025: 5,977,246).","QUELIMMUNE (SCD-PED) FDA-approved Feb 2024; first commercial shipment July 2024; 4 hospital customers as of Q1 2025.","NEUTRALIZE-AKI adult pivotal trial 37% enrolled (74 of 200 subjects); 14 of 30 sites activated; CMS covers trial costs.","Four FDA Breakthrough Device Designations: adult AKI, cardiorenal syndrome w/ LVAD, hepatorenal syndrome, chronic dialysis.","Zero interest-bearing debt; cash use $11.3M YTD through Q3 2024; raised ~$20M new equity through Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195652,"accession_number":"0001213900-24-112673","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical receives Nasdaq delisting notice for failing minimum market value rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified SeaStar on Dec 24, 2024 that it failed to regain compliance with $35M minimum market value of listed securities.","Securities (ICU, ICUCW) are subject to delisting from Nasdaq on Jan 3, 2025 unless Company appeals by Dec 31, 2024.","Company intends to appeal delisting determination before Nasdaq Hearings Panel; appeal stays delisting pending outcome.","SeaStar was previously notified of non-compliance on June 24, 2024 and has not regained compliance since."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195651,"accession_number":"0000950170-24-138428","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SeaStar Medical faces derivative lawsuit over alleged false FDA approval statements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed Dec 13, 2024 in US District Court for Colorado by shareholder Jose Lazo.","Defendants include CEO Eric Schlorff, former CFO, and certain current/former directors.","Alleges false/misleading statements about FDA prospects for Selective Cytopheretic Device and deficient internal controls.","Claims violations of Exchange Act Sections 14(a), 10(b), 21D, plus breach of fiduciary duty and unjust enrichment.","Seeks damages, restitution, and injunctive relief; substantially similar to a prior class action disclosed July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195650,"accession_number":"0000950170-24-131042","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SeaStar Medical stockholders approve reduction of authorized shares to 450M and ratification of Nasdaq issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1 ratified issuance of shares upon conversion of notes/warrants to maintain Nasdaq listing: 1,404,488 for, 48,859 against, 1,783 abstain (1,112,485 broker non-votes).","Proposal 2 approved amendment to reduce authorized common shares from 500M to 450M: 2,485,697 for, 80,561 against.","Proposal 3 to adjourn meeting if needed approved: 2,420,064 for, 117,955 against, 29,596 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195649,"accession_number":"0000950170-24-126487","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical reports Q3 revenue of $67,500 from first commercial sales of QUELIMMUNE; net loss narrows to $4.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.","Net loss $4.5M ($1.10/share) vs $7.2M ($9.02/share) in Q3 2023; cash $2.1M as of Sep 30.","Eliminated all $9M+ long-term debt during 2024; no long-term debt outstanding.","FDA granted Breakthrough Device Designation for SCD in chronic dialysis (4th designation).","NEUTRALIZE-AKI adult trial: 59 subjects enrolled, record October enrollment; 12 clinical sites."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":68000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195648,"accession_number":"0001213900-24-089442","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SeaStar Medical settles Nuwellis dispute over pediatric SCD distribution; pays $900K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves breach-of-contract dispute with former distributor Nuwellis.","Company to pay $900,000 in three installments by December 31, 2024.","Original exclusive distribution agreement for pediatric SCD product terminated in August 2024 after notice of breach.","Settlement terms are confidential except for payment details disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211911,"accession_number":"0001213900-24-071230","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SeaStar Medical enters $25M ATM equity facility with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows sale of up to $25M in common stock via at-the-market offerings on Nasdaq.","Company pays 3% commission on gross sales; no obligation to sell any shares.","Sales will be made under existing Form S-3 shelf registration (File No. 333-275968).","Proceeds from any sales are for general corporate purposes; offering may be suspended by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211910,"accession_number":"0000950170-24-096362","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.","First commercial sales of QUELIMMUNE for pediatric AKI in July 2024; launched with U.S. distribution partner.","Adult NEUTRALIZE-AKI trial enrolled 42 subjects at 9 sites; CMS granted Category B coverage for Medicare/Medicaid.","Completed $10M registered direct offering in July; cash ~$6.9M as of July 31 after reducing debt by $2.7M.","Board expanded with three new directors; expects adult PMA approval in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211909,"accession_number":"0001013762-24-000173","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"SeaStar Medical raises $10M via registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 947,868 shares at $10.55 each, raising ~$10M gross proceeds.","Concurrent private placement of warrants to purchase 947,868 shares at $10.55, exercisable for 5 years.","Offering closed July 11, 2024; net proceeds for working capital, capex, and debt repayment.","H.C. Wainwright acted as exclusive placement agent; fees 7% of gross proceeds plus warrants.","Placement agent warrants cover 66,351 shares at $13.1875 (125% of offering price)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211908,"accession_number":"0000950170-24-082415","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Shareholder class action lawsuit filed against SeaStar Medical alleging misstatements about FDA approval and restatement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Plaintiff Forrest A K Wells filed putative class action on July 5, 2024 in Colorado federal court.","Alleges material misstatements/omissions regarding FDA approval of product candidates and business operations.","Claims under Section 10(b) of Exchange Act against Company, CEO, and former CFO; also Section 20(a).","Seeks compensatory and other damages; Company intends to vigorously defend the action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211907,"accession_number":"0000950170-24-081874","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical self-reports potential Nasdaq rule violation for share issuance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company notified Nasdaq of possible violation of Listing Rule 5635(d)(2) regarding convertible-note conversion and warrant exercise.","$9.8M convertible notes issued in four tranches with warrants equal to 25% of conversion amount per March 2023 SPA.","Aug and Dec 2023 amendments added $2.2M notes each, reset conversion price to $0.20, and issued 4,765,620 (190,624 post-R/S) and 1,055,416 (42,216 post-R/S) additional warrants.","Company requests Nasdaq determination; committed to full shareholder-approval compliance and adviser engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211906,"accession_number":"0000950170-24-080011","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"SeaStar Medical redeems 126,330 warrants for $449,735 from 3i, LP; terminates related notes.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeemed 126,330 warrants at $3.56 each from institutional investor 3i, LP for total $449,734.80.","Payment: $100,000 paid July 1, 2024; $349,734.80 deferred to Aug 27, 2024, with 7% annual interest.","All obligations under the March 2023 securities purchase agreement, convertible notes, and warrants are discharged.","Warrants were previously classified as liabilities on balance sheet due to certain features."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230706,"accession_number":"0000950170-24-079054","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SeaStar Medical receives Nasdaq MVLS deficiency notice; regains bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 24, 2024, SeaStar received Nasdaq deficiency letter for MVLS below $35M minimum for 35 consecutive days.","Compliance period ends Dec 23, 2024; no imminent delisting.","On June 27, 2024, Nasdaq confirmed bid price compliance regained after 1-for-25 reverse stock split on June 7.","Company evaluating options to address MVLS deficiency, including possible extension or appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230705,"accession_number":"0000950170-24-071622","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SeaStar Medical redeems $0.7M convertible notes, converts $1.3M into equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redeemed $0.7M of Investor D convertible notes at 200% of Conversion Amount per prior agreement.","Converted $0.6M principal and $0.7M interest/make-whole into 2,321,429 (92,858 post-split) common shares.","All Investor D notes are now retired; Investor D retains warrants for 3,158,086 (126,323 post-split) shares.","Warrants have weighted-average exercise price of $0.55 ($13.75 post-split)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230704,"accession_number":"0000950170-24-071087","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SeaStar Medical appoints three new directors; three depart in board refresh","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Andres Lobo resigned June 5, 2024; John Neuman appointed as Class I director same day.","Jennifer A. Baird and Bernadette N. Vincent elected at June 4 annual meeting.","Bruce Rodgers and Richard Russell did not stand for reelection at the meeting.","John Neuman is retired Dow VP of Global Financial Accounting; brings 30 years finance experience.","Board reconstituted as SeaStar Medical transitions to commercial-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230703,"accession_number":"0000950170-24-070915","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"SeaStar Medical announces 1-for-25 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:25 ratio effective June 7, 2024; trading on split-adjusted basis from June 10, 2024 under symbol ICU.","Post-split shares outstanding approximately 3.1 million; no fractional shares issued (rounded up to whole share).","Purpose: to increase share price and regain compliance with Nasdaq's $1.00 minimum bid price requirement.","All outstanding stock options, warrants, and convertible securities proportionally adjusted in accordance with the split ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230702,"accession_number":"0000950170-24-068696","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SeaStar Medical stockholders approve tripling of equity plan shares and warrant issuance to institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Collins, Baird, Vincent with >25M votes each; no director received majority against.","Approved amendment to 2022 Omnibus Plan increasing authorized shares from 3,278,457 to 9,778,457.","Approved issuance of 20%+ of outstanding shares upon exercise of Series A (10.8M) and Series B (5.4M) warrants to a single institutional investor.","Ratified WithumSmith+Brown as independent auditor for FY2024 with 44.6M for, 1.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230701,"accession_number":"0000950170-24-059518","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SeaStar Medical Q1 net loss $12.7M, cash rises to $5M; Quelimmune launch imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.7M ($0.19 per share) vs $7.1M ($0.54) in Q1 2023; no revenue recorded.","Cash and cash equivalents $5.0M as of March 31, 2024, up from $176K at Dec 31, 2023.","Quelimmune Pediatric received FDA approval in Feb 2024; initial sales expected in coming weeks at five children's hospitals.","NEUTRALIZE-AKI adult trial enrolled 31 subjects at eight sites; regulatory approval expected H2 2025.","January 2024 $9M at-the-market offering and appointment of David A. Green as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230700,"accession_number":"0000929638-24-001521","cik":1831868,"company_name":"SeaStar Medical Holding Corp","ticker":"ICU","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SeaStar Medical lowers stockholder meeting quorum to 33 1/3%, removes 'Acting in Concert' definition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum for stockholder meetings reduced from majority to 33 1/3% of outstanding common stock.","Board removed 'Acting in Concert' definition and related provisions from Section 2.12(a) and (b).","Second Amended and Restated Bylaws approved April 12, 2024, effective same date.","Changes affect ability to block actions and proxy contest rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14349236.016759776,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-18T23:59:59+00:00|230700"}